Replies to post #82019 on Biotech Values

[urche]

Arixtra---GSK, MNTA

This is a minor update on my prior post in which I shared my surprise that a medium size hospital where I worked has adopted Arixtra, deleting Lovenox from the formulary.

Dew's points are compelling why this is not likely to be significant issue for Momenta, despite my concern that just prior to generic enoxaparin hitting the market, Arixtra may be able to pull off a strong increase in market share.

One of the reasons DEW raised for being unconcerned is that Arixtra is not approved for acute coronary syndrome. Be that as it may, this NH hospital, which has a strong cardiology dep't and does PCI, is in fact using Arixtra (off label) for ACS.

Once again, the suddenness of this shift in a pretty conservative hospital took me by surprise. But, let's not lose sight of the fact that when generic enoxaparin hits the market, the cost savings will rapidly annul any market share gained by Arixtra.

urche

[RockRat]

Alchemia (aussie company) and Dr. Reddy's are teaming up to make Arixtra generic (it's been off patent for a few years). They announced today that their plant will be inspected in Novmeber, so maybe next year? Further, Arixtra is now indicated for treatment of DVT. ACS is pending, I gather, dunno the odds there. Obviously, still not an immediate concern, but a bit mores so than it was at the time of this post to which I am replying.

Regards, RockRat